Developing a next-generation insulin sensitizer for the treatment of NASH
Cirius Therapeutics (formerly Octeta Therapeutics) is developing MSDC-0602K, a next-generation insulin sensitizer, for the treatment of nonalcoholic steatohepatitis (NASH). NASH affects approximately 16 million Americans, and untreated can progress to cirrhosis and liver transplant. MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novel insulin sensitizing mechanism of action, MSDC-0602K has potential to resolve the underlying pathophysiology of NASH. The company is led by Frazier EIRs Bob Baltera, Howard Dittrich, and Brian Farmer.